Grant Pickering - Oct 1, 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact
Stock symbol
PCVX
Transactions as of
Oct 1, 2024
Transactions value $
-$6,069,861
Form type
4
Date filed
10/3/2024, 04:17 PM
Previous filing
Sep 5, 2024
Next filing
Oct 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Sale -$411K -3.62K -0.78% $113.38 462K Oct 1, 2024 Direct F1, F2
transaction PCVX Common Stock Sale -$810K -7.09K -1.54% $114.27 455K Oct 1, 2024 Direct F1, F3
transaction PCVX Common Stock Sale -$493K -4.29K -0.94% $114.99 450K Oct 1, 2024 Direct F1, F4
transaction PCVX Common Stock Options Exercise $107K +20K +4.44% $5.35 470K Oct 1, 2024 Direct
transaction PCVX Common Stock Sale -$488K -4.31K -0.92% $113.35 466K Oct 1, 2024 Direct F1, F5
transaction PCVX Common Stock Sale -$1.08M -9.43K -2.02% $114.20 456K Oct 1, 2024 Direct F1, F6
transaction PCVX Common Stock Sale -$720K -6.27K -1.37% $114.93 450K Oct 1, 2024 Direct F1, F7
transaction PCVX Common Stock Options Exercise $107K +20K +4.44% $5.35 470K Oct 1, 2024 Direct
transaction PCVX Common Stock Sale -$555K -4.9K -1.04% $113.37 465K Oct 1, 2024 Direct F1, F8
transaction PCVX Common Stock Sale -$1.1M -9.63K -2.07% $114.28 456K Oct 1, 2024 Direct F1, F9
transaction PCVX Common Stock Sale -$629K -5.47K -1.2% $114.98 450K Oct 1, 2024 Direct F1, F10
holding PCVX Common Stock 142K Oct 1, 2024 By Children's Trust F11
holding PCVX Common Stock 142K Oct 1, 2024 By Children's Trust F12

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -20K -7.73% $0.00 239K Oct 1, 2024 Common Stock 20K $5.35 Direct F13
transaction PCVX Stock Option (right to buy) Options Exercise $0 -20K -8.38% $0.00 219K Oct 1, 2024 Common Stock 20K $5.35 Direct F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $112.76 to $113.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $113.76 to $114.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $114.77 to $115.275. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 The price reported is a weighted-average price. The shares were sold at prices ranging from $112.705 to $113.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 The price reported is a weighted-average price. The shares were sold at prices ranging from $113.705 to $114.68. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7 The price reported is a weighted-average price. The shares were sold at prices ranging from $114.705 to $115.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F8 The price reported is a weighted-average price. The shares were sold at prices ranging from $112.745 to $113.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F9 The price reported is a weighted-average price. The shares were sold at prices ranging from $113.76 to $114.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F10 The price reported is a weighted-average price. The shares were sold at prices ranging from $114.80 to $115.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F11 Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
F12 Shares are held directly by a trust for the benefit of the Reporting Person's son.
F13 Stock Option is fully vested and exercisable.